154 related articles for article (PubMed ID: 29228742)
21. Evaluation of the Glasgow Prognostic Score in patients receiving chemoradiotherapy for stage III and IV esophageal cancer.
Kimura J; Kunisaki C; Makino H; Oshima T; Ota M; Oba M; Takagawa R; Kosaka T; Ono HA; Akiyama H; Endo I
Dis Esophagus; 2016 Nov; 29(8):1071-1080. PubMed ID: 26471766
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract][Full Text] [Related]
23. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
[TBL] [Abstract][Full Text] [Related]
24. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
25. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
Agemi Y; Shimokawa T; Sasaki J; Miyazaki K; Misumi Y; Sato A; Aida S; Ishii M; Nakamura Y; Naoki K; Okamoto H
PLoS One; 2019; 14(1):e0210499. PubMed ID: 30653558
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer.
Dolan RD; Daly L; Sim WMJ; Fallon M; Ryan A; McMillan DC; Laird BJ
Clin Nutr; 2020 Sep; 39(9):2889-2895. PubMed ID: 31926762
[TBL] [Abstract][Full Text] [Related]
28. Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer.
Rocha BMM; Dolan RD; Paiva CE; McGovern J; Paiva BSR; Preto DD; McMillan DC; Maia YCP; Laird BJ
J Pain Symptom Manage; 2023 Apr; 65(4):348-357. PubMed ID: 36493981
[TBL] [Abstract][Full Text] [Related]
29. First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status.
Hwang JE; Kim HN; Kim DE; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
Exp Ther Med; 2012 Oct; 4(4):562-568. PubMed ID: 23170106
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy.
Aziz A; Fritsche HM; Gakis G; Kluth LA; Hassan Fa; Engel O; Dahlem R; Otto W; Gierth M; Denzinger S; Schwentner C; Stenzl A; Shariat SF; Fisch M; Burger M; Rink M
Urol Oncol; 2014 Nov; 32(8):1141-50. PubMed ID: 24856977
[TBL] [Abstract][Full Text] [Related]
31. [Clinical efficacy and prognostic factors for cryoablation patients with advanced hepatocellular carcinoma].
Chang XJ; Lu YY; Bai WL; Chen Y; An LJ; Zhou L; Wang H; Wu Y; Liu Z; Lou M; Zeng Z; Su SH; Yang YP
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):759-63. PubMed ID: 22409849
[TBL] [Abstract][Full Text] [Related]
32. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.
Buccheri G; Ferrigno D; Tamburini M
Eur J Cancer; 1996 Jun; 32A(7):1135-41. PubMed ID: 8758243
[TBL] [Abstract][Full Text] [Related]
33. The novel pretreatment immune prognostic index discriminates survival outcomes in locally advanced non-operative esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: a 6-year retrospective study.
Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Zheng Q; Zheng H; Wang Z; Li H; Liu L; Li J; Yao Q
Transl Oncol; 2022 Jul; 21():101430. PubMed ID: 35452997
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study.
Martinez-Salamanca JI; Shariat SF; Rodriguez JC; Chromecki TF; Ficarra V; Fritsche HM; Kassouf W; Matsumoto K; Cabello LO; Seitz C; Tritschler S; Walton TJ; Zattoni F; Novara G
BJU Int; 2012 Apr; 109(8):1155-61. PubMed ID: 21883847
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome.
Trestini I; Sperduti I; Sposito M; Kadrija D; Drudi A; Avancini A; Tregnago D; Carbognin L; Bovo C; Santo A; Lanza M; D'Onofrio M; Tortora G; Bria E; Milella M; Pilotto S
ESMO Open; 2020 May; 5(3):e000689. PubMed ID: 32424067
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy.
Haefner MF; Lang K; Krug D; Koerber SA; Uhlmann L; Kieser M; Debus J; Sterzing F
J Radiat Res; 2015 Jul; 56(4):742-9. PubMed ID: 25907360
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
39. Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study.
Guo F; Han T; Liu Z; Song X; Zhang Q; Kong X; Li C; Li Z; Li C; Qu S; Zheng Z; Piao Y; Han Y; Xie X
Onco Targets Ther; 2015; 8():1581-8. PubMed ID: 26170693
[TBL] [Abstract][Full Text] [Related]
40. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study.
Sánchez-Lara K; Turcott JG; Juárez E; Guevara P; Núñez-Valencia C; Oñate-Ocaña LF; Flores D; Arrieta O
Nutr Cancer; 2012; 64(4):526-34. PubMed ID: 22489794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
